Nutraceutical company Deccan Health Care reports 25% revenue jump, highlights Q2 FY25 growth

Deccan Health Care Limited, a prominent player in the nutraceutical industry, has reported a remarkable performance for Q2 FY25, showcasing substantial growth across all key financial parameters. The company, listed on the Bombay Stock Exchange (BSE: 542248), revealed a 25% quarterly increase in revenue, reaching ₹1,882.1 lakhs, alongside a 27.5% rise in EBITDA and an astonishing 45.6% jump in Profit After Tax (PAT).

Q2 FY25: A snapshot of stellar growth

The unaudited financial results for Q2 FY25 highlight Deccan Health Care’s solid momentum in the competitive nutraceutical market. Quarter-on-quarter (QoQ) revenue rose to ₹1,882.1 lakhs, while year-on-year (YoY) figures reflected a 9.5% increase. Gross profit saw a QoQ improvement of 18.2% to ₹745.6 lakhs, maintaining a healthy margin of 39.6%.

On the profitability front, EBITDA surged to ₹110.9 lakhs, marking a QoQ growth of 27.5%, with the EBITDA margin slightly improving to 5.9%. PAT delivered a notable boost, climbing by 45.6% QoQ to ₹53.7 lakhs, underscoring the company’s effective cost management and operational efficiency.

Half-yearly performance reinforces robust growth

Deccan Health Care’s H1 FY25 results echoed the company’s sustained growth trajectory. Revenue climbed 19.2% YoY to ₹3,388.2 lakhs, while EBITDA reached ₹197.9 lakhs, up 6.7% YoY. PAT for the half-year period rose 7.5% YoY to ₹90.6 lakhs.

Innovation drives strategic initiatives

A significant highlight was the company’s focus on combating anemia through its Straya Iron Fruit Bar. This innovative product, enriched with natural iron and 13 herbs, contributes to the Anemia Mukt Bharat initiative by offering a healthier alternative to conventional supplements. The company has collaborated with organizations such as the Ganga Aruna Foundation and IFFCO TOKIO to ensure widespread distribution and awareness.

Outlook and future growth engines

Chairman and Managing Director Dr. Minto Purshotam Gupta attributed the company’s success to rising demand, strong brand equity, and operational efficiency. He emphasized that expanding private-label manufacturing contracts and enhancing nationwide visibility through DWC and HS initiatives would further boost performance in the coming quarters.

Deccan Health Care’s continuous efforts to strengthen its market share and innovate within the nutraceutical sector position it as a leader in addressing diverse health and wellness goals.

Dr. Gupta underscored the company’s focus on sustainable growth and innovation. He explained that increasing market visibility through direct wholesale coverage (DWC) and high-street (HS) initiatives remains a priority. According to Dr. Gupta, these efforts align with the company’s vision of enhancing shareholder value while addressing consumer health needs.